Latest news with #CEST
Yahoo
2 days ago
- Business
- Yahoo
CORRECTION! KALDVIK AS (KLDVK): Announcement of Q1 2025 results and new refinancing package
KALDVIK AS (KLDVK) reports operating income in Q1 of EURm 48.4 (EURm 31.1), while the operating profit/loss before fair value adjustment of biomass and production tax was positive of EURm 9.8 (EURm 2.4). Harvest amounted to 6,383 tonnes in Q1 2025 (3,986 tonnes) Web cast will be at 09:00 (CEST)/ 07:00 Icelandic time on 28 May 2025 on the following link: NEW REFINANCING PACKAGE Further, Kaldvik has initiated a process to refinance the company through a new debt package and equity and has received confirmation of a new and improved bank financing package from its existing lenders. In connection with the refinancing, it is a condition for the new financing that the company raises a net cash amount of approx. EUR 45 million in new equity. The company is in the process of launching such an equity raise, with strong backing from its majority shareholder, Austur Holding AS. Attached is the presentation and report for Q1 2025, which also includes further information on the refinancing package. An updated company presentation has also been uploaded to the company's website Kaldvik, 28 May 2025 Contact: Robert Robertsson, CFO of KALDVIK AS: +354 843 0086(mobile) This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Róbert Róbertsson, CFO of Kaldvik AS, on 28 May 2025 at 07:00 CEST. Attachments Kaldvik Q1 2025 presentation Kaldvik Q1 2025 ReportError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
CORRECTION! KALDVIK AS (KLDVK): Announcement of Q1 2025 results and new refinancing package
KALDVIK AS (KLDVK) reports operating income in Q1 of EURm 48.4 (EURm 31.1), while the operating profit/loss before fair value adjustment of biomass and production tax was positive of EURm 9.8 (EURm 2.4). Harvest amounted to 6,383 tonnes in Q1 2025 (3,986 tonnes) Web cast will be at 09:00 (CEST)/ 07:00 Icelandic time on 28 May 2025 on the following link: NEW REFINANCING PACKAGE Further, Kaldvik has initiated a process to refinance the company through a new debt package and equity and has received confirmation of a new and improved bank financing package from its existing lenders. In connection with the refinancing, it is a condition for the new financing that the company raises a net cash amount of approx. EUR 45 million in new equity. The company is in the process of launching such an equity raise, with strong backing from its majority shareholder, Austur Holding AS. Attached is the presentation and report for Q1 2025, which also includes further information on the refinancing package. An updated company presentation has also been uploaded to the company's website Kaldvik, 28 May 2025 Contact: Robert Robertsson, CFO of KALDVIK AS: +354 843 0086(mobile) This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Róbert Róbertsson, CFO of Kaldvik AS, on 28 May 2025 at 07:00 CEST. Attachments Kaldvik Q1 2025 presentation Kaldvik Q1 2025 ReportError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 days ago
- Business
- Business Wire
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET (1:35 p.m. CEST). Live webcast and replay: One-on-one meetings with the management team can be scheduled with conference representatives or directly with Medincell ( About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals
Yahoo
2 days ago
- Business
- Yahoo
Medincell Executives to Join Fireside Chat at Jefferies Global Healthcare Conference 2025
MONTPELLIER, France, May 28, 2025--(BUSINESS WIRE)--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell's (Paris:MEDCL) corporate overview during a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 7:35 a.m. ET (1:35 p.m. CEST). Live webcast and replay: One-on-one meetings with the management team can be scheduled with conference representatives or directly with Medincell ( About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86 Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023 Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94 Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Havila Kystruten AS: Notice of Annual General Meeting May 12th, 2025.
The Board of Directors of Havila Kystruten AS hereby gives notice of the AnnualGeneral Meeting. The meeting will take place on Thursday, June 12th, 2025 at10:00 Annual General Meeting will be held as a digital meeting with electronicvoting via Lumi platform. It is also possible to cast votes or give proxyauthorizations in advance. Notice of the Annual General Meeting together withall relevant documents is available at information can be found in the notice of the Annual General Meetingwhich is attached Executive Officer: Bent Martini, +47 905 99 650Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114 Attachment Notice of Annual General Meeting_2025_Havila Kystruten ASError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
